Cover Image
市場調查報告書

亞太地區的癲癇治療藥市場:強化功效·安全性的下一代抗癲癇藥(AED)來擴充治療的選擇

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

出版商 GBI Research 商品編碼 297629
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
亞太地區的癲癇治療藥市場:強化功效·安全性的下一代抗癲癇藥(AED)來擴充治療的選擇 Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
出版日期: 2014年03月14日 內容資訊: 英文
簡介

亞太地區癲癇治療藥的市場規模在2012年的時點達到了11億美金,一般預測到2019年前更將以年複合成長率(CAGR)4.7%的速度成長,並將在2019年達到15億美金。中國、印度發病率之高,中國藉由改善市場連結提升了治療藥的普及率,新功能機制的治療藥預計將上市等,是市場成長的要素。同時也有專利到期而成為學名藥的需求,這些都可能限制市場的成長。

本報告提供亞太地區各國癲癇治療法的相關市場分析,提供疾病概要和主要的治療模式,已上市產品概要(安全性·功效等),目前開發中的治療藥管道資訊,地區整體及主要國家市場趨勢預測(今後8年的預測值),資本交易·產業聯盟的動向等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 病因
  • 病理處理
  • 共生病症/併發症
  • 診斷
  • 預測
  • 治療效率
  • 治療選擇
    • 離子通道調控劑
    • 促進GABA的效能
    • 興奮性氨基酸抑制劑
    • 突觸調節劑
  • 非藥物療法
    • 肺葉切除(Lobectomy)及病灶切除手術(Lesionectomy)
    • 產酮飲食及改良式艾金斯低糖飲食療法
    • 迷走神經刺激

第3章 癲癇的治療環境

  • 概況
  • Lyrica (pregabalin)
  • Lamictal (lamotrigine)
  • Keppra (levetiracetam)
  • Zonegran (zonisamide)
  • Vimpat (lacosamide)
  • Aptiom/Zebinix (eslicarbazepine acetate)
  • Fycompa (perampanel)
  • Trobalt/Potiga (ezogabine/retigabine)
  • Banzel/Inovelon (rufinamide)
  • 上市產品的功效·安全性比較

第4章 癲癇治療藥的平台

  • 開發平台的整體情形
  • 各行動機制的平台
  • 臨床實驗
    • 失敗率
    • 參加的患者數和臨床實驗的規模
    • 臨床實驗的期間
  • 有前途的開發平台候補
    • Brivaracetam(UCB開發)
    • Ganaxolone(Marinus Pharmaceuticals開發)

第5章 癲癇的治療藥市場未來預測(今後6年份)

  • 各地區市場趨勢
    • 亞太地區的主要國家
    • 中國
    • 印度
    • 日本
    • 澳洲
  • 推動及阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素

第6章 資本交易與策略性的企業整合

  • 資本交易分析
  • 研究開發(R&D):共同開發契約
  • 研究開發(R&D):授權合約

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC324MR

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -

  • A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
  • In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
  • A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
  • Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
  • Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
  • In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Asia-Pacific Epilepsy Therapeutics Market Continues to Grow as New Drugs Emerge, says GBI Research

The epilepsy therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%, forecasts business intelligence provider GBI Research.

According to the firm's latest report*, China and India are expected to show the fastest growth over the forecast period, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%.

Vijaya Vulapalli, Senior Analyst for GBI Research, says: "With a high epilepsy prevalence, China and India have large treatment populations, which are expected to increase further in the future due to better healthcare access and an improvement in treatment gaps."

GBI Research states that the epilepsy sector is still dominated by older generation Anti-Epileptic Drugs (AEDs), such as carbamazepine, valproate, oxcarbazepine and phenytoin, which account for a combined share of over 60% of the APAC region's market. Historically, these AEDs have had poor safety and tolerability profiles.

However, second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets.

Vulapalli concludes: "Approximately 20 to 30% of epilepsy patients fail to respond to treatment with existing AEDs. This population forms a sizeable chunk of the market, which is promising for new entrants. Both Fycompa and Trobalt have the potential to address refractory epilepsy patient needs when launched in their respective markets."

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

This report provides analysis of the epilepsy market within the Asia-Pacific region covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Overview
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology
  • 2.5. Pathophysiology
  • 2.6. Co-morbidities/Complications
  • 2.7. Diagnosis
  • 2.8. Prognosis
  • 2.9. Treatment Efficacy
  • 2.10. Treatment Options
    • 2.10.1. Ion Channel Modulators
    • 2.10.2. GABA-ergic Facilitation
    • 2.10.3. Excitatory Amino Acid Inhibitors
    • 2.10.4. Synaptic Modulators
  • 2.11. Non-pharmacological Management
    • 2.11.1. Lobectomy and Lesionectomy
    • 2.11.2. Ketogenic Diet and Modified Atkins Diet
    • 2.11.3. Vagus Nerve Stimulation

3. Epilepsy Therapeutic Landscape

  • 3.1. Overview
  • 3.2. Lyrica (pregabalin)
  • 3.3. Lamictal (lamotrigine)
  • 3.4. Keppra (levetiracetam)
  • 3.5. Zonegran (zonisamide)
  • 3.6. Vimpat (lacosamide)
  • 3.7. Aptiom/Zebinix (eslicarbazepine acetate)
  • 3.8. Fycompa (perampanel)
  • 3.9. Trobalt/Potiga (ezogabine/retigabine)
  • 3.10. Banzel/Inovelon (rufinamide)
  • 3.11. Comparative Efficacy and Safety of Marketed Products

4. Pipeline for Epilepsy Therapeutics

  • 4.1. Overall Pipeline
  • 4.2. Pipeline by Mechanism of Action
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate
    • 4.3.2. Patient Enrolment and Clinical Trial Size
    • 4.3.3. Clinical Trial Duration
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. Brivaracetam - UCB
    • 4.4.2. Ganaxolone - Marinus Pharmaceuticals

5. Epilepsy Therapeutics Market Forecast to 2019

  • 5.1. Geographical Markets
    • 5.1.1. Key Asia-Pacific Markets
    • 5.1.2. China
    • 5.1.3. India
    • 5.1.4. Japan
    • 5.1.5. Australia
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Deals Analysis
  • 6.2. Research and Development Co-development Agreements
  • 6.3. Research and Development Licensing Agreements

7. Appendix

  • 7.1. Abbreviations
  • 7.2. References
  • 7.3. References for Heat Maps
  • 7.4. Pipeline Products by Phase
    • 7.4.1. Discovery
    • 7.4.2. Preclinical
    • 7.4.3. IND-filed and Phase 0
    • 7.4.4. Phase I
    • 7.4.5. Phase II
    • 7.4.6. Phase III
    • 7.4.7. Pre-registration
  • 7.5. Market Forecasting Data Tables to 2019
    • 7.5.1. Asia-Pacific
    • 7.5.2. China
    • 7.5.3. India
    • 7.5.4. Japan
    • 7.5.5. Australia
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
  • Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
  • Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
  • Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
  • Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
  • Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
  • Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
  • Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
  • Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
  • Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012-2019
  • Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012-2019
  • Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012-2019
  • Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012-2019
  • Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012
  • Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
  • Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009-2013
  • Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009-2013
  • Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009-2013
  • Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009-2013
  • Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
  • Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
  • Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
  • Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013
  • Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
  • Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
  • Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012-2019
  • Figure 14: Epilepsy Therapeutics, China, Market Size, 2012-2019
  • Figure 15: Epilepsy Therapeutics, India, Market Size, 2012-2019
  • Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012-2019
  • Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012-2019
  • Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006-2013
  • Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006-2013
  • Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006-2013
  • Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006-2013
  • Figure 22: GBI Research Market Forecasting Model
Back to Top